e-Drug3D

637

ACITRETIN


INN
ACITRETIN

(is an active metabolite)

cas 55079-83-9
CLASS

DERMATOLOGICALS
ANTIPSORIATIC
KERATOLYTIC AGENTS

ROUTE (list)

ORAL

ATC code

D05BB02

PK parameters

F 72 PERCENT
Tmax 2.7 HOUR
PPB 99.9 PERCENT
t1/2 49 HOUR

Target

TARGET RETINOIC ACID RECEPTOR (RAR)
RETINOIC X RECEPTOR (RXR)

DrugCentral

Retinoic acid receptor alpha UNIPROT P10276 RARA

Retinoic acid receptor gamma UNIPROT P13631 RARG

Download SDF file (2Z,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid

Formula:
C21H26O3

Calculated chemical properties:

MW 325.41
NB_atoms 24
XLogP 3.83
PSA 42.909
NB_HD 0
NB_HA 3
fsp3 0.29
Lipinski(0=no;1=yes) 1

FDA
NDA 019821 (pdf not found) INN (ACITRETIN) SORIATANE (STIEFEL LABS INC) APPROVAL= AP YEAR= 1996 DISCONTINUED
NDA 091455 (pdf not found) INN (ACITRETIN) ACITRETIN (BARR LABS INC) APPROVAL= AP YEAR= 2013
NDA 202897 (pdf not found) INN (ACITRETIN) ACITRETIN (TEVA PHARMS USA) APPROVAL= AP YEAR= 2013
NDA 204633 (pdf not found) INN (ACITRETIN) ACITRETIN (SIGMAPHARM LABS LLC) APPROVAL= AP YEAR= 2015
NDA 202148 (pdf not found) INN (ACITRETIN) ACITRETIN (MYLAN) APPROVAL= AP YEAR= 2015
NDA 202552 (pdf not found) INN (ACITRETIN) ACITRETIN (IMPAX LABS INC) APPROVAL= AP YEAR= 2015
NDA 203707 (pdf not found) INN (ACITRETIN) ACITRETIN (MYLAN) APPROVAL= AP YEAR= 2015 DISCONTINUED
NDA 217774 (pdf not found) INN (ACITRETIN) ACITRETIN (ALEMBIC) APPROVAL= AP YEAR= 2024

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL